

---

**CORRIGENDUM**

## The way forward in HCV treatment — finding the right path

*Michael P. Manns, Graham R. Foster, Jürgen K. Rockstroh, Stefan Zeuzem, Fabien Zoulim and Michael Houghton*

*Nature Reviews Drug Discovery* **6**, 991–1000 (December 2007) | doi:10.1038/nrd2411

For Figure 3 (page 995), compound TMC435350 is in Phase I and not in Phase II.

Also, the acknowledgements should read:

The authors would like to thank R. Douglas and L. O'Mahony for help in preparing the manuscript; this support was funded by Novartis. M.P.M., J.K.R., S.Z. acknowledge the support of Hep-Net, a network sponsored by BMBF, and M.P.M., S.Z., F.Z. are supported by VIRGIL, an EU6 Framework Project.